Literature DB >> 19955859

Advances in the treatment of metastatic colorectal cancer.

Carla Kurkjian1, Shivaani Kummar.   

Abstract

The treatment of metastatic colorectal cancer has undergone major advances yielding significant improvements in survival over the past decade. These advances have evolved due to the benefits of combination chemotherapy and the incorporation of biologic therapy. However, as we struggle to provide optimum care while sparing patients ineffective therapy and undue cost, the importance of tailored therapy to maximize benefit will become increasingly important. This article reviews the major advances in the treatment of patients with metastatic colorectal cancer and the burgeoning developments in individualized therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19955859      PMCID: PMC2789349          DOI: 10.1097/MJT.0b013e3181907ed9

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  63 in total

1.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.

Authors:  R Porschen; A Bermann; T Löffler; G Haack; K Rettig; Y Anger; G Strohmeyer
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

4.  Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.

Authors:  N Wolmark; H Rockette; E Mamounas; J Jones; S Wieand; D L Wickerham; H D Bear; J N Atkins; N V Dimitrov; A G Glass; E R Fisher; B Fisher
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

5.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

6.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

Review 7.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

8.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

Authors:  F Levi; B Perpoint; C Garufi; C Focan; P Chollet; P Depres-Brummer; R Zidani; S Brienza; M Itzhaki; S Iacobelli
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

9.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

Authors:  P Thirion; S Michiels; J P Pignon; M Buyse; A C Braud; R W Carlson; M O'Connell; P Sargent; P Piedbois
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

10.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Authors:  E Marcuello; A Altés; A Menoyo; E Del Rio; M Gómez-Pardo; M Baiget
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  15 in total

1.  Treatment and Survival of Medicare Beneficiaries with Colorectal Cancer: A Comparative Analysis Between a Rural State Cancer Registry and National Data.

Authors:  Pallavi B Rane; S Suresh Madhavan; Usha Sambamoorthi; Kalidindi Sita; Sobha Kurian; Xiaoyun Pan
Journal:  Popul Health Manag       Date:  2016-07-15       Impact factor: 2.459

Review 2.  Management of stage IV rectal cancer: palliative options.

Authors:  Sean M Ronnekleiv-Kelly; Gregory D Kennedy
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).

Authors:  Hong-hua Ding; Wei-dong Wu; Tao Jiang; Jun Cao; Zheng-yi Ji; Jia-hua Jin; Jing-jue Wang; Wei-feng Song; Li-wei Wang
Journal:  Tumour Biol       Date:  2014-12-23

4.  Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient.

Authors:  Veli Berk; Sevda Ismailogullari; Halil Donmez; Halit Karaca; Mevlude Inanc; Metin Ozkan
Journal:  Med Oncol       Date:  2011-04-02       Impact factor: 3.064

5.  RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.

Authors:  Annemarie Boleij; Véronique Tack; Aliki Taylor; George Kafatos; Sophie Jenkins-Anderson; Lien Tembuyser; Els Dequeker; J Han van Krieken
Journal:  BMC Cancer       Date:  2016-10-26       Impact factor: 4.430

Review 6.  LncRNAs as Regulators of Autophagy and Drug Resistance in Colorectal Cancer.

Authors:  Mercedes Bermúdez; Maribel Aguilar-Medina; Erik Lizárraga-Verdugo; Mariana Avendaño-Félix; Erika Silva-Benítez; Cesar López-Camarillo; Rosalío Ramos-Payán
Journal:  Front Oncol       Date:  2019-10-02       Impact factor: 6.244

7.  Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX).

Authors:  Hiroyuki Komori; Toru Beppu; Yasuo Sakamoto; Yuji Miyamoto; Hiromitsu Hayashi; Katsunori Imai; Hidetoshi Nitta; Masayuki Watanabe; Hideo Baba
Journal:  Case Rep Gastrointest Med       Date:  2014-06-17

8.  Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells.

Authors:  Seyung S Chung; Pranabananda Dutta; David Austin; Piwen Wang; Adam Awad; Jaydutt V Vadgama
Journal:  Oncotarget       Date:  2018-08-31

9.  A National Survey of Medical Oncologist's Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab.

Authors:  Kimberly A Lowe; Laura Sangaré; Rachel Bergstresser; Michelle McNamara; George Kafatos; Tamer Garawin
Journal:  Dermatol Ther (Heidelb)       Date:  2019-05-03

10.  Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab.

Authors:  Yuta Ushida; Eiji Shinozaki; Keisho Chin; Mitsukuni Suenaga; Daisuke Takahari; Masato Ozaka; Mariko Ogura; Takashi Ichimura; Takeru Wakatsuki; Kensei Yamaguchi
Journal:  Case Rep Oncol       Date:  2018-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.